It can be hypothesized that pdC1INH replacement therapy may have a modulatory impact on autoimmune diseases in C1INH-HAE (occurrence and/or severity) by increasing C1-INH, C4, and/or C2 as suggested in some studies (36). This evidence concerns the gene C4A and hereditary angioedema.